Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 23;3(24):4291-4297.
doi: 10.1182/bloodadvances.2019001062.

Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents

Andishe Attarbaschi  1 , Oussama Abla  2 , Leila Ronceray  1 , Shweta Bansil  3 , Simon Bomken  4 , Birgit Burkhardt  5 , Francecso Ceppi  6 , Alan K S Chiang  7 , Hema Dave  8 , Alina Fedorova  9 , Michael Henry  10 , Janez Jazbec  11 , Edita Kabickova  12 , Rishi S Kotecha  13 , Jelena Lazic  14 , Jan Loeffen  15 , Natalia Miakova  16 , Tomoo Osumi  17 , Marta Pillon  18 , Apostolos Pourtsidis  19 , Charlotte Rigaud  20 , Gevorg Tamamyan  21 , Sneha Tandon  2 , Anne Uyttebroeck  22 , Jamie Verdu-Amoros  23 , Wilhelm Woessmann  24 , Grazyna Wrobel  25 , Lisa Giulino-Roth  3
Affiliations

Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents

Andishe Attarbaschi et al. Blood Adv. .

Erratum in

Abstract

  1. Children with PCNSL and no immunodeficiency have a good outcome when treated by a histological subtype–driven and radiation-free protocol.

  2. New treatment guidelines are needed for PCNSL in children and adolescents with an underlying immunodeficiency.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: L.G.-R. has acted as a consultant for Janssen, ADC Therapeutics, and Celgene. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
EFS and OS rates of the 75 PCNSL patients according to risk factors. EFS (A) and OS (B) of the 75 PCNSL patients. (C) EFS of the 56 PCNSL patients without a preexisting disorder vs 14 PCNSL patients with a preexisting disorder. (D) EFS of the 36 PCNSL patients with 1 lesion vs 32 PCNSL patients with ≥2 lesions. (E) EFS of the 68 PCNSL patients who received therapies that included high-dose methotrexate vs 6 PCNSL patients who did not receive high-dose methotrexate. (F) EFS of the 55 PCNSL patients who received therapies with high-dose cytarabine vs 19 PCNSL patients who did not receive high-dose cytarabine.
See this image and copyright information in PMC

References

    1. Abla O, Sandlund JT, Sung L, et al. . A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer. 2006;47(7):880-885. - PubMed
    1. Giulino-Roth L, Abla O, Batchelor TT. Management of primary central nervous system lymphoma in children. Hematology Am Soc Hematol Educ Program. 2016;2016:386-389. - PMC - PubMed
    1. Thorer H, Zimmermann M, Makarova O, et al. . Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Münster protocols for systemic lymphoma. Haematologica. 2014;99(11):e238-e241. - PMC - PubMed
    1. Attarbaschi A, Carraro E, Abla O, et al. ; European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfur t-Münster (i-BFM) Study Group . Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016;101(12):1581-1591. - PMC - PubMed
    1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281-1288. - PubMed

Publication types